Lonafarnib Production Cost Reports

The report provides a detailed analysis essential for establishing a Lonafarnib production plant. It encompasses all critical aspects necessary for Lonafarnib production, including the cost of Lonafarnib production, Lonafarnib plant cost, Lonafarnib production costs, and the overall Lonafarnib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Lonafarnib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Lonafarnib is a medication used to treat certain rare genetic disorders like progeria by blocking the farnesyltransferase enzyme. It is utilised as a drug in the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies, which is a rare genetic disorder that causes accelerated ageing.

It is mainly used in clinical settings to slow the progression of these conditions and improve the quality of life for patients. It is also being explored for its potential use in treating other diseases associated with premature ageing and some types of cancer. Additionally, it is also explored in clinical trials as a potential therapeutic option for diseases caused by abnormal cell growth and function.

The demand for Lonafarnib is mainly supported by its use in treating Hutchinson-Gilford Progeria Syndrome (HGPS) and other rare laminopathy disorders, which strongly contribute to its market growth. Its application as a medication in the treatment of related progeroid disorders also boosts its demand in the healthcare and speciality pharmaceutical sectors. Its ability to slow disease progression and improve patient outcomes significantly strengthens its medical importance.

The increasing focus on orphan drugs, improved genetic testing, and rising awareness of premature-ageing disorders further contribute to market growth. In addition, factors like the availability and cost of specialised raw materials, strict regulatory requirements, and the need for high-quality production practices associated with rare-disease therapies largely impact industrial Lonafarnib procurement.

Improvements in production methods, reliability of suppliers, responsible production practices, and smooth distribution networks also influence its procurement strategies globally. Moreover, ongoing research into new therapeutic uses and rising attention toward rare disease management continue to support demand in the medical industry.

Raw Material for Lonafarnib Production

According to the Lonafarnib production plant project report, the major raw materials for Lonafarnib production includes N-Boc-4-(methanesulfonyloxy)piperidine and (1R,3S)-3-(bromomethyl)-1-(chloromethyl)-2,3-dihydro-1H-benzo[f]quinoline.

Production Process of Lonafarnib

The extensive Lonafarnib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Lonafarnib begins with a tricyclic compound, N-Boc-4-(methanesulfonyloxy)piperidine, which reacts with (1R,3S)-3-(bromomethyl)-1-(chloromethyl)-2,3-dihydro-1H-benzo[f]quinoline under basic conditions (LDA and quinine) to form a chiral intermediate with high enantiomeric purity. Then, the Boc protecting group is removed under acidic conditions, and the product crystallises as N-acetyl-L-phenylalaninate. Further, N-Boc-piperidine-4-acetic acid is coupled to this intermediate using standard amide bond formation reagents (HOBT, EDCI, DMF). After coupling, the Boc group is removed under acidic conditions. The final step involves the formation of a urea linkage using urea and N-methylpyrrolidone (NMP) at high temperature, which ultimately produces Lonafarnib.

Lonafarnib is a white to beige crystalline powder with no noticeable odour and is usually handled as a solid at room temperature. Its molecular formula is C27H31Br2ClN4O2, and its molar mass is 638.82 g/mol. The compound has a density of about 1.54 g/cm³, and it shows very low solubility in water, though it dissolves to some extent in solvents like chloroform and methanol. The melting point of the compound is around 214–216 °C for the monohydrate form, with the anhydrous material melting slightly higher, around 222–223 °C. The boiling point of the compound is around 710 °C. The compound is handled with care in research and pharmaceutical settings, as it may cause harm if swallowed or inhaled. Extended or repeated exposure to the compound can pose health risks, which makes protective clothing and proper handling practices advisable.